A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa

被引:568
作者
Hasford, J
Pfirrmann, M
Hehlmann, R
Allan, NC
Baccarani, M
Kluin-Nelemans, JC
Alimena, G
Steegmann, JL
Ansari, H
机构
[1] Univ Munich, Inst Med Informat Biometry & Epidemiol, IBE, D-81377 Munich, Germany
[2] Univ Heidelberg, Med Klin 3, D-6800 Mannheim, Germany
[3] Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland
[4] Univ Udine, Cattedra Ematol, I-33100 Udine, Italy
[5] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands
[6] Univ Rome La Sapienza, Dipartimento Biopatol Umana, Sez Ematol, I-00185 Rome, Italy
[7] Hosp Univ Princesa, Serv Hematol, Madrid, Spain
[8] Biometr Ctr Therapeut Studies, D-8000 Munich, Germany
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1998年 / 90卷 / 11期
关键词
D O I
10.1093/jnci/90.11.850
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Interferon alfa is a conservative and widely used alternative to bone marrow transplantation in treatment of patients with early chronic myeloid leukemia (CML), A meta-analysis was conducted to develop a reliable prognostic scoring system for estimation of survival of patients with CML treated with interferon alfa, Methods: Patients treated in prospective studies, including major randomized trials, were separated into learning and validation samples. Cox regression analysis and the minimum P-value approach were used to identify prognostic factors for patient survival and to discover groups in the learning sample with the greatest differences in survival. These findings were then validated by applying the new scoring system to patients in the validation sample, Results: We collected data on 1573 patients who were participants in 14 studies involving 12 institutions; 1303 patients (learning sample, n = 981; validation sample, n = 322) were eligible for inclusion in this analysis, and their median survival time was 69 months (range, 1-117 months). Because two previously described prognostic scoring systems failed to discriminate risk groups satisfactorily, we developed a new scoring system that utilizes the following covariates: age, spleen size, blast count, platelet count, eosinophil count, and basophil count. Among 908 patients with complete data in the learning sample, three distinct risk groups were identified (median survival times of 98 months [n = 369; 40.6%], 65 months [n = 406; 44.7%], or 42 months [n = 133;14.6%]; two-sided logrank test, P less than or equal to.0001). The ability of the new scoring system to discriminate these risk groups was confirmed by analysis of 285 patients with complete data in the validation sample (two-sided logrank test, P = .0002), Conclusions: A new prognostic scoring system for estimating survival of patients with CML treated with interferon alfa has been developed and validated through use of a large dataset.
引用
收藏
页码:850 / 858
页数:9
相关论文
共 34 条
  • [1] ALIMENA G, 1988, BLOOD, V72, P642
  • [2] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE
    ALLAN, NC
    RICHARDS, SM
    SHEPHERD, PCA
    [J]. LANCET, 1995, 345 (8962) : 1392 - 1397
  • [3] DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS
    ALTMAN, DG
    LAUSEN, B
    SAUERBREI, W
    SCHUMACHER, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 829 - 835
  • [4] ANSARI H, 1993, MED INFORMATIK BIOME, V76, P168
  • [5] BRANDMAIER R, 1993, P 18 ANN SAS US GROU, P1032
  • [6] Breiman L., 1984, Classification and Regression Trees, DOI DOI 10.2307/2530946
  • [7] Byar DP, 1984, CANCER CLIN TRIALS, P423
  • [8] Collett D., 1994, Modelling Survival Data in Medical Research
  • [9] *DEP HEM, 1996, BONE MARROW TRAN S3, V17, pS19
  • [10] INTERFERON ALPHA-2A IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE - RESULTS OF THE SPANISH GROUP
    FERNANDEZRANADA, JM
    LAVILLA, E
    ODRIOZOLA, J
    GARCIALARANA, J
    LOZANO, M
    PARODY, R
    GIRALDO, MP
    CARBONELL, F
    FERRO, MT
    STEEGMANN, JL
    [J]. LEUKEMIA & LYMPHOMA, 1993, 11 : 175 - 179